US 11,858,984 B2
Anti-S100A8/A9 antibody and use thereof
Masakiyo Sakaguchi, Okayama (JP); Shinichi Toyooka, Okayama (JP); Shuta Tomida, Okayama (JP); Kazuhiko Shien, Okayama (JP); Hiroki Sato, Okayama (JP); Rie Kinoshita, Okayama (JP); Junichiro Futami, Okayama (JP); Kota Araki, Okayama (JP); Mikio Okazaki, Okayama (JP); Eisaku Kondo, Niigata (JP); Yusuke Inoue, Maebashi (JP); and Akira Yamauchi, Kurashiki (JP)
Assigned to National University Corporation Okayama University, Okayama (JP); Niigata University, Niigata (JP); and National University Corporation Gunma University, Gunma (JP)
Appl. No. 17/050,384
Filed by NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY, Okayama (JP); NIIGATA UNIVERSITY, Niigata (JP); NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY, Maebashi (JP); and KAWASAKI GAKUENN EDUCATIONAL FOUNDATION, Kurashiki (JP)
PCT Filed Apr. 15, 2019, PCT No. PCT/JP2019/016100
§ 371(c)(1), (2) Date Oct. 23, 2020,
PCT Pub. No. WO2019/208290, PCT Pub. Date Oct. 31, 2019.
Claims priority of application No. 2018-087576 (JP), filed on Apr. 27, 2018.
Prior Publication US 2021/0054061 A1, Feb. 25, 2021
Int. Cl. C07K 16/00 (2006.01); C07K 16/46 (2006.01); C07K 16/24 (2006.01); A61P 11/00 (2006.01); A61P 35/04 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/24 (2013.01) [A61P 11/00 (2018.01); A61P 35/04 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)] 20 Claims
 
1. A pharmaceutical composition, comprising an antibody or an antibody fragment thereof as an active ingredient, the antibody or the antibody fragment thereof having a neutralizing antibody affinity for a heterodimer of S100A8 and S100A9, and wherein said antibody or said antibody fragment thereof comprises a combination of:
a heavy chain variable region (VH CDR) comprising the amino acid sequence set forth in SEQ ID NO: 7, 8, and 9; and
(ii) a light chain variable region (VL CDR) comprising the amino acid sequence set forth in SEQ ID NO: 22, 23, and 24.